Trials / Unknown
UnknownNCT04984954
Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Shexiang Baoxin Pill on Coronary Microvascular Dysfunction
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 264 (estimated)
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Objective to evaluate the effect of Shexiang Baoxin Pill on myocardial ischemia in patients with coronary microvascular dysfunction (non obstructive coronary heart disease) through a randomized, double-blind, placebo-controlled clinical multicenter study.At the same time, the effects of exercise tolerance and quality of life were also observed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MUSK pill | This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up |
Timeline
- Start date
- 2021-01-28
- Primary completion
- 2023-12-31
- Completion
- 2024-06-30
- First posted
- 2021-08-02
- Last updated
- 2021-08-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04984954. Inclusion in this directory is not an endorsement.